This author has not written his bio yet.
But we are proud to say that Bastian Arlt contributed 86 entries already.
The patent application 20240316057 focuses on a pulsatile release formulation for caffeine, designed to control its release profile over a specific time frame. The formulation is targeted at therapeutic and non-therapeutic uses — enhancing mental alertness and addressing conditions like morning grogginess or fatigue. By using a release-controlling polymeric system, the caffeine release can be […]
The patent application titled “Modified Release Gamma-Hydroxybutyrate (GHB) Formulations Having Improved Pharmacokinetics” (US20240148685) focuses on improving the delivery of GHB, a substance used for treating sleep disorders like narcolepsy, through modified-release formulations. The goal is to optimize GHB’s absorption, enhancing patient convenience and compliance by reducing the need for multiple nightly doses. The key innovation […]
The patent application US20240139215A1 focuses on the development of controlled release formulations for highly lipophilic physiologically active substances, such as cannabinoids. These substances tend to have high lipid solubility (log P of 4 or more), making them difficult to deliver in a controlled and effective manner. This patent addresses the need for efficient controlled release […]
The United States Patent Application US20240024263 focuses on methods of administering gamma-hydroxybutyrate (GHB) in combination with divalproex sodium (DVP), particularly for treating conditions like narcolepsy. The aim is to co-administer these drugs without altering their dosage or efficacy. The patent emphasizes how DVP affects GHB’s pharmacokinetics, allowing adjustments to minimize side effects while ensuring therapeutic […]
The development of modified release gamma-hydroxybutyrate represents a major advancement in narcolepsy therapy, aiming to improve both patient compliance and treatment effectiveness. Traditional formulations of gamma-hydroxybutyrate (GHB) require multiple nightly doses, which can disrupt sleep and reduce overall quality of life. The patented formulation described in US11896572B2 introduces a novel modified release system that extends […]
The following patent on “Extended release compositions comprising pyridostigmine” employs CELLETS® as starter spheres made of Microcrystalline Cellulose. Please, read below a summary. US Patent 20240299305 addresses an extended-release formulation of pyridostigmine, a drug primarily used to treat myasthenia gravis (MG). The goal of the patent is to create a dosage form that prolongs the […]
The following patent on “Extended-release compositions comprising atomoxetine” employs CELLETS® as starter spheres made of Microcrystalline Cellulose. Please, read below a summary. United States Patent Application 20240299307 focuses on an extended-release formulation of atomoxetine, commonly used for treating ADHD. The patent describes a unique pellet-based drug delivery system designed to control the release of atomoxetine […]
This article “Influence of Polymer Film Thickness on Drug Release from Fluidized Bed Coated Pellets and Intended Process and Product Control” was published on Pharmaceutics 2024, 16(10), 1307; https://doi.org/10.3390/pharmaceutics16101307, under free licence on October 08, 2024 by Marcel Langner, Florian Priese, and Bertram Wolf. We performed modifications of the text for better readability. Abstract Background/Objectives: Coated drug pellets […]
Abstract Compaction pressure can induce an undesirable solid-state polymorphic transition in drugs, fragmentation, loss of coated pellet integrity, and the decreased viability and vitality of microorganisms. Thus, the excipients with increased plasticity can be considered as an option to decrease the undesirable effects of compaction pressure. This study aims to increase the plasticity (to reduce […]